JPH10506902A - 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 - Google Patents
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物Info
- Publication number
- JPH10506902A JPH10506902A JP8512100A JP51210096A JPH10506902A JP H10506902 A JPH10506902 A JP H10506902A JP 8512100 A JP8512100 A JP 8512100A JP 51210096 A JP51210096 A JP 51210096A JP H10506902 A JPH10506902 A JP H10506902A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- antigen
- cea
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 182
- 239000000427 antigen Substances 0.000 title claims abstract description 175
- 102000036639 antigens Human genes 0.000 title claims abstract description 175
- 241000700605 Viruses Species 0.000 title claims abstract description 174
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 230000003308 immunostimulating effect Effects 0.000 title claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 161
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 125
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 201000010099 disease Diseases 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000028993 immune response Effects 0.000 claims abstract description 30
- 244000000010 microbial pathogen Species 0.000 claims abstract description 13
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 12
- 230000004936 stimulating effect Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 205
- 241000700618 Vaccinia virus Species 0.000 claims description 56
- 230000003053 immunization Effects 0.000 claims description 38
- 238000002649 immunization Methods 0.000 claims description 38
- 230000001575 pathological effect Effects 0.000 claims description 34
- 210000004881 tumor cell Anatomy 0.000 claims description 29
- 230000003612 virological effect Effects 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 23
- 239000003242 anti bacterial agent Substances 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 16
- 208000009956 adenocarcinoma Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 229940088710 antibiotic agent Drugs 0.000 claims description 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108700020796 Oncogene Proteins 0.000 claims description 12
- -1 B7.2 Proteins 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 9
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 102100023123 Mucin-16 Human genes 0.000 claims description 8
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 108060008724 Tyrosinase Proteins 0.000 claims description 8
- 102000003425 Tyrosinase Human genes 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 229940124551 recombinant vaccine Drugs 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 8
- 238000005215 recombination Methods 0.000 claims description 8
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 7
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 7
- 230000001613 neoplastic effect Effects 0.000 claims description 7
- 108700042226 ras Genes Proteins 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims description 5
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 5
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 5
- 101800001271 Surface protein Proteins 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 101150047061 tag-72 gene Proteins 0.000 claims description 5
- 208000008732 thymoma Diseases 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 208000000666 Fowlpox Diseases 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 230000002155 anti-virotic effect Effects 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000000711 cancerogenic effect Effects 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 68
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 65
- 241000699670 Mus sp. Species 0.000 description 65
- 239000013598 vector Substances 0.000 description 49
- 210000001744 T-lymphocyte Anatomy 0.000 description 41
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 36
- 102100038358 Prostate-specific antigen Human genes 0.000 description 34
- 206010046865 Vaccinia virus infection Diseases 0.000 description 28
- 208000007089 vaccinia Diseases 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 25
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 150000007523 nucleic acids Chemical group 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 230000005867 T cell response Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 230000000139 costimulatory effect Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 241000271566 Aves Species 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 108010084313 CD58 Antigens Proteins 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 6
- 108010008707 Mucin-1 Proteins 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101150089247 B7 gene Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101001039696 Homo sapiens Lysophospholipid acyltransferase 7 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000012270 DNA recombination Methods 0.000 description 3
- 101150073066 F13L gene Proteins 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 3
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 241000287219 Serinus canaria Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 description 3
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000012921 fluorescence analysis Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000001589 lymphoproliferative effect Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 101150028074 2 gene Proteins 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 108010045634 B7 Antigens Proteins 0.000 description 2
- 102000005738 B7 Antigens Human genes 0.000 description 2
- 101150045267 CEA gene Proteins 0.000 description 2
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 2
- 241000178270 Canarypox virus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101100118548 Drosophila melanogaster Egfr gene Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000002494 anti-cea effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940126580 vector vaccine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100027271 40S ribosomal protein SA Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 240000007571 Consolida ajacis Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 241000269820 Euthynnus affinis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005740 Freeman reaction Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000744718 Homo sapiens YTH domain-containing family protein 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 101100438951 Mus musculus Cd86 gene Proteins 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 238000003684 Perkin reaction Methods 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241001067453 Therion Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 102100039674 YTH domain-containing family protein 3 Human genes 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000002153 familial abdominal 3 aortic aneurysm Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 病的状態の抗原をコードする1以上の遺伝子またはその一部をウイルス ゲノムまたはその一部中に取り込んでいる第1の組み換えウイルスと、免疫刺激 分子をコードする1以上の遺伝子またはその一部をウイルスゲノムまたはその一 部中に取り込んでいる第2の組み換えウイルスとを単独で含むか、または外因の 免疫刺激分子、化学療法薬、抗生物質、抗ウイルス薬または抗菌薬と組み合わせ て含む組成物。 2. ウイルスがレトロウイルス、鶏痘、カナリア痘、豚痘、アデノウイルス 、ワクシニアウイルスおよびポリオウイルスから成る群から選択される、請求項 1に記載の組成物。 3. 病的状態が癌または病原性微生物である、請求項1に記載の組成物。 4. 癌が原発性または転移性である、請求項3に記載の組成物。 5. 癌が非ホドキンリンパ腫、白血病、ホドキンリンパ腫、肺癌、肝臓癌、 黒色腫、腺癌、胸腺腫および肉腫から成る群から選択される、請求項4に記載の 組成物。 6. 病原性微生物がウイルス、バクテリウム、原生動物、または酵母である 、請求項3に記載の組成物。 7. 病原性ウイルスが、HIV、肝炎ウイルス、ヒトパピローマウイルス、 ウマ脳炎ウイルス、単純ヘルペスウイルスまたはインフルエンザウイルスである 、請求項6に記載の組成物。 8. 抗原が腫瘍関連抗原である、請求項4に記載の組成物。 9. 腫瘍関連抗原が、胎児腫瘍性抗原、MART−1、Mage−1、Ma ge−3、gp100、チロシナーゼ、CEA、PSA、CA−125、erb −2、Muc−1、Muc−2、点変異ras癌遺伝子、点変異p53癌遺伝子 、およびTAG−72から成る群から選択される、請求項8に記載の組成物。 10. 免疫刺激分子が、IL−2、B7.1、B7.2、ICAM−1、L FA−3、CD72、GM−CSF、TNFα、INFγ、IL−12、IL− 6およびそれらの組み合わせから成る群から選択される、請求項1に記載の組成 物。 11. 抗原がCEAであり、免疫刺激分子がB7.1、B7.2あるいはB 7.1とB7.2である、請求項10に記載の組成物。 12. 請求項1に記載の組成物の有効量を単独で、または外因の免疫刺激分 子と組み合わせて哺乳動物に投与することを含む哺乳動物の病気を防止する方法 であって、上記量が上記病的状態を防止または改善するのに有効である上記の方 法。 13. 請求項1に記載の組成物および薬学的に許容できる担体を含む医薬組 成物。 14. 請求項1に記載の組成物によってインビトロで病的状態の細胞を感染 させ、上記感染した細胞を病的状態の細胞に罹患した哺乳動物に投与することを 含む、哺乳動物の病的状態の細胞に対する免疫応答を強化する方法。 15. 細胞が腫瘍細胞、遺伝的に欠陥のある細胞、または病原性微生物に感 染した細胞である、請求項14に記載の方法。 16. インビボで病的状態の細胞を請求項1に記載の組成物の有効量で直接 感染させることを含む、哺乳動物の病的状態の細胞に対する免疫応答を強化する 方法。 17. B7−1をコードする遺伝子またはその一部、B7−2をコードする 遺伝子またはその一部、またはB7−1とB7−2とをコードする遺伝子または その一部をウイルスゲノムまたはその一部中に取り込んでいる組み換えワクシニ アウイルスを含む組み換えワクシニアウイルス。 18. 病的状態の抗原に特異的な抗体またはその抗原結合断片を含み、請求 項1に記載の組成物による免疫感作によって引き出された抗体またはその抗原結 合断片。 19. 病的状態の抗原をコードする1以上の遺伝子またはその一部と、免疫 刺激分子をコードする1以上の遺伝子またはその一部とをウイルスゲノムまたは その一部中に取り込んでいる単独、またはまたは外因の免疫刺激分子、化学療法 薬、抗生物質、抗ウイルス薬または抗菌薬と組み合わせた組み換えウイルス。 20. 抗原が腫瘍関連抗原である請求項19に記載の組み換えウイルス。 21. 腫瘍関連抗原が、胎児腫瘍性抗原、MART−1、Mage−1、M age−3、gp100、チロシナーゼ、CEA、PSA、CA−125、er b−2、Muc−1、Muc−2、点変異ras癌遺伝子、点変異p53癌遺伝 子、およびTAG−72から成る群から選択される、請求項20に記載の組み換 えウイルス。 22. 免疫刺激分子が、IL−2、B7.1、B7.2、ICAM−1、L FA−3、CD72、GM−CSF、TNFα、INFγ、IL−12、IL− 6およびそれらの組み合わせから成る群から選択される、請求項19に記載の組 み換えウイルス。 23. 抗原がCEAであり、免疫刺激分子がB7.1、B7.2あるいはB 7.1とB7.2である、請求項20に記載の組み換えウイルス。 24. 請求項19に記載の組み換えウイルスと薬学的に許容できる担体とを 含む医薬組成物。 25. 病的状態の抗原を反映する結合部位を有する抗体をコードする1以上 の遺伝子またはその一部をウイルスゲノムまたはその一部中に取り込んでいる第 1の組み換えウイルスと、免疫刺激分子をコードする1以上の遺伝子またはその 一部をウイルスゲノムまたはその一部中に取り込んでいる第2の組み換えウイル スとを単独で、または外因の免疫刺激分子、化学療法薬、抗生物質、抗ウイルス 薬または抗菌薬と組み合わせて含む組成物。 26. 病的状態の抗原を反映する結合部位を有する抗体をコードする1以上 の遺伝子またはその一部と、免疫刺激分子をコードする1以上の遺伝子またはそ の一部とをウイルスゲノムまたはその一部中に取り込んでいる組み換えウイルス 単独、または外因の免疫刺激分子、化学療法薬、抗生物質、抗ウイルス薬または 抗菌薬と組み合わせた上記組み換えウイルス。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31726894A | 1994-10-03 | 1994-10-03 | |
US08/317,268 | 1994-10-03 | ||
US08/483,316 US6045802A (en) | 1994-10-03 | 1995-06-07 | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
US08/483,316 | 1995-06-07 | ||
PCT/US1995/012624 WO1996010419A2 (en) | 1994-10-03 | 1995-10-02 | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004048693A Division JP4078319B2 (ja) | 1994-10-03 | 2004-01-23 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
JP2006291632A Division JP4160612B2 (ja) | 1994-10-03 | 2006-10-26 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10506902A true JPH10506902A (ja) | 1998-07-07 |
JP3907698B2 JP3907698B2 (ja) | 2007-04-18 |
Family
ID=26980864
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51210096A Expired - Lifetime JP3907698B2 (ja) | 1994-10-03 | 1995-10-02 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
JP2004048693A Expired - Lifetime JP4078319B2 (ja) | 1994-10-03 | 2004-01-23 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
JP2006291632A Expired - Lifetime JP4160612B2 (ja) | 1994-10-03 | 2006-10-26 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004048693A Expired - Lifetime JP4078319B2 (ja) | 1994-10-03 | 2004-01-23 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
JP2006291632A Expired - Lifetime JP4160612B2 (ja) | 1994-10-03 | 2006-10-26 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
Country Status (12)
Country | Link |
---|---|
US (3) | US6548068B1 (ja) |
EP (2) | EP0784483B1 (ja) |
JP (3) | JP3907698B2 (ja) |
AT (1) | ATE197765T1 (ja) |
AU (1) | AU688606B2 (ja) |
CA (1) | CA2201587C (ja) |
DE (1) | DE69519521T2 (ja) |
DK (1) | DK0784483T3 (ja) |
ES (1) | ES2154738T3 (ja) |
GR (1) | GR3035458T3 (ja) |
PT (1) | PT784483E (ja) |
WO (1) | WO1996010419A2 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008518583A (ja) * | 2003-05-16 | 2008-06-05 | アヴェンティス パストゥール インコーポレイテッド | 癌の予防または治療のための腫瘍抗原 |
JP2009254390A (ja) * | 1998-12-09 | 2009-11-05 | Usa Government | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
JP2012524075A (ja) * | 2009-04-17 | 2012-10-11 | グローブイミューン,インコーポレイテッド | 癌に対する併用免疫療法組成物および方法 |
JP2013528197A (ja) * | 2010-06-10 | 2013-07-08 | インターベツト・インターナシヨナル・ベー・ベー | 抗腫瘍組成物 |
JP2018515141A (ja) * | 2015-05-15 | 2018-06-14 | リーバー ジェネティクス シーオー., エルティーディー.Reber Genetics Co., Ltd. | 新規のバキュロウイルスベクター及び使用の方法 |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6816194A (en) * | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
JP4475683B2 (ja) * | 1996-07-25 | 2010-06-09 | アメリカ合衆国 | 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス |
WO1998004728A1 (en) * | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
WO1998037095A2 (en) | 1997-02-24 | 1998-08-27 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
US6730512B2 (en) * | 1997-04-09 | 2004-05-04 | Amdl, Inc. | Combination immunogene therapy |
TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
ATE421888T1 (de) * | 1997-08-13 | 2009-02-15 | Uab Research Foundation | Impfung durch topische verwendung genetischer vektoren |
US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
AU757600B2 (en) * | 1998-02-20 | 2003-02-27 | University Of Miami | Modified heat shock protein-antigenic peptide complex |
US8119395B1 (en) * | 1998-02-27 | 2012-02-21 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
US7279168B2 (en) | 1998-05-01 | 2007-10-09 | Texas A & M University System | Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof |
BR9910153A (pt) * | 1998-05-01 | 2001-10-02 | Texas A & M System | ácido nucléico e polipeptìdeos de cd80 de felino, cd80 de felino, cd28 de felino e ctla-4 de felino |
WO1999057295A1 (en) * | 1998-05-01 | 1999-11-11 | Schering-Plough Ltd. | Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof |
EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
WO2001016320A1 (en) * | 1999-08-30 | 2001-03-08 | Ludwig Institute For Cancer Research | Isolated nona and decapeptides which bind to hla molecules, and the use thereof |
EP1409534A2 (de) * | 1999-09-27 | 2004-04-21 | Gabriele Pecher | Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung |
JP2003510341A (ja) * | 1999-10-06 | 2003-03-18 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 細胞ターゲッティング組成物及びそれらを使用する方法 |
WO2001030847A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
EP1741782B1 (en) * | 2000-05-10 | 2011-06-22 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
GB0111442D0 (en) * | 2001-05-10 | 2001-07-04 | Isis Innovation | Method for preparing recombinant virus |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20040091995A1 (en) * | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
PT1496939E (pt) | 2002-04-09 | 2007-11-22 | Sanofi Pasteur Ltd | ''ácido nucleico de cea modificado e vectores de expressão'' |
EP1369491A1 (en) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
US20040101522A1 (en) * | 2002-09-12 | 2004-05-27 | Therion Biologics Corporation | Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivo |
EP1556082A1 (en) * | 2002-10-22 | 2005-07-27 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
DE602004018927D1 (de) * | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
WO2005005465A2 (en) * | 2003-07-08 | 2005-01-20 | Board Of Regents, University Of Texas System | Methods and compositions to enhance immune responses via recall antigens |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
DK1697399T3 (en) | 2003-12-12 | 2017-03-06 | Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi | Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences |
WO2005120566A1 (en) * | 2004-06-11 | 2005-12-22 | Tai-Gyu Kim | Dendrite cells transduced with recombinant adenovirus advcea which generate cea-specific cytotoxic t lymphocytes, vaccine and pharmaceutical composition comprising the same |
WO2007097370A1 (ja) | 2006-02-22 | 2007-08-30 | Riken | CD1dリガンドをパルスした、標的抗原及びCD1dの共発現細胞による免疫療法 |
DK1989224T3 (da) | 2006-02-24 | 2011-02-14 | Us Gov Health & Human Serv | Immunogene peptider og anvendelsesmetoder |
CA2649688A1 (en) | 2006-03-14 | 2007-09-20 | Oregon Health & Science University | Methods for detecting a mycobacterium tuberculosis infection |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
JP5596980B2 (ja) | 2007-02-28 | 2014-10-01 | アメリカ合衆国 | ブラキュリポリペプチドおよび使用方法 |
WO2008156655A2 (en) * | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
EP2173368A1 (en) * | 2007-07-18 | 2010-04-14 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
EP2752193B1 (en) | 2008-03-03 | 2017-01-11 | The University of Miami | Allogeneic cancer cell-based immunotherapy |
JP5779352B2 (ja) | 2008-03-14 | 2015-09-16 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 複製欠損フラビウイルスワクチンおよびワクチンベクター |
EP2274001A4 (en) | 2008-03-20 | 2012-08-01 | Univ Miami | GP96 THERMAL IMPACT PROTEIN VACCINATION AND METHODS OF USE |
WO2010005474A1 (en) * | 2008-06-16 | 2010-01-14 | Emergent Product Development Gaithersburg Inc. | Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens |
JPWO2010061930A1 (ja) | 2008-11-28 | 2012-04-26 | 独立行政法人理化学研究所 | CD1d及び標的抗原の共発現アロ細胞を用いた免疫療法 |
DE102008055194A1 (de) | 2008-12-30 | 2010-07-08 | Federal-Mogul Wiesbaden Gmbh | Gleitelement |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
WO2011063263A2 (en) | 2009-11-20 | 2011-05-26 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
EP2559762A4 (en) | 2010-04-13 | 2013-11-06 | Riken | NEW MONOCLONAL ANTIBODY ANTI-HSP90 |
US9804163B2 (en) | 2010-08-06 | 2017-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for prostate cancer and methods for their detection |
EP2675473A1 (en) | 2011-02-15 | 2013-12-25 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
ES2733211T3 (es) | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
PT2850431T (pt) | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
AU2015289773A1 (en) | 2014-07-15 | 2017-02-02 | Immune Design Corp. | Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector |
CA2975191C (en) | 2015-02-06 | 2023-05-09 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
KR20170138996A (ko) | 2015-02-25 | 2017-12-18 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양을 위한 단일면역요법으로서 또는 면역 체크포인트 차단제와 조합된 불활성화 비복제성 변형 백시니아 바이러스 안카라의 용도 |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3283088A4 (en) | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
EP3374374B1 (en) | 2015-11-09 | 2020-03-04 | Immune Design Corp. | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
EP3400009A2 (en) | 2016-01-05 | 2018-11-14 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
AU2017223460A1 (en) | 2016-02-23 | 2018-09-13 | Immune Design Corp. | Multigenome retroviral vector preparations and methods and systems for producing and using same |
AU2017222686B2 (en) | 2016-02-25 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
JP7034080B2 (ja) | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | ヒトflt3lを発現する組換えmvaまたはmvaδe3lおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 |
KR20230101931A (ko) | 2016-04-15 | 2023-07-06 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
KR102536850B1 (ko) | 2016-04-15 | 2023-05-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
WO2018071405A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
JP7386083B2 (ja) | 2017-03-16 | 2023-11-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | Cd80バリアント免疫調節タンパク質及びその使用 |
CA3053812A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
PT3596116T (pt) | 2017-03-16 | 2023-12-04 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de pd-l1 variante e suas utilizações |
SG11201908280SA (en) | 2017-03-30 | 2019-10-30 | Univ Queensland | "chimeric molecules and uses thereof" |
WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
EP4400174A2 (en) | 2017-09-01 | 2024-07-17 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
CN111801347A (zh) | 2017-10-10 | 2020-10-20 | 高山免疫科学股份有限公司 | Ctla-4变体免疫调节蛋白和其用途 |
SG11202003078VA (en) | 2017-10-18 | 2020-05-28 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
WO2019155708A1 (ja) * | 2018-02-09 | 2019-08-15 | 株式会社タツノ | 充填装置 |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
AU2019345151A1 (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
KR20210070338A (ko) * | 2018-10-04 | 2021-06-14 | 에스큐지 바이오테크놀로지스 컴퍼니 | 항원 제시 세포 기능을 증진시키기 위한 생체분자의 세포내 전달 |
EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
KR20220035032A (ko) | 2019-04-17 | 2022-03-21 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도 |
CN113840914A (zh) | 2019-05-14 | 2021-12-24 | 国立大学法人鸟取大学 | 诱导细胞融合的痘苗病毒及其应用 |
WO2021029368A1 (ja) | 2019-08-09 | 2021-02-18 | 国立研究開発法人理化学研究所 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
CA3178882A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
CN116322727A (zh) | 2020-11-17 | 2023-06-23 | 国立大学法人鸟取大学 | 新型基因重组痘苗病毒及其应用 |
EP4332216A1 (en) | 2021-04-30 | 2024-03-06 | Riken | Artificial adjuvant vector cell capable of inducing immune response to coronavirus, pharmaceutical composition containing said cell, and use applications of said cell and said pharmaceutical composition |
PE20240641A1 (es) | 2021-05-07 | 2024-04-04 | Alpine Immune Sciences Inc | Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
US20240033347A1 (en) | 2022-07-08 | 2024-02-01 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5206353A (en) | 1988-07-23 | 1993-04-27 | The United States Of America As Represented By The Department Of Health And Human Services | CD-4/cytotoxic gene fusions |
CA2066053C (en) * | 1989-08-18 | 2001-12-11 | Harry E. Gruber | Recombinant retroviruses delivering vector constructs to target cells |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
EP0584266B1 (en) * | 1991-05-06 | 2003-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
AU6816194A (en) | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
-
1995
- 1995-10-02 EP EP95935264A patent/EP0784483B1/en not_active Expired - Lifetime
- 1995-10-02 ES ES95935264T patent/ES2154738T3/es not_active Expired - Lifetime
- 1995-10-02 DE DE69519521T patent/DE69519521T2/de not_active Expired - Lifetime
- 1995-10-02 DK DK95935264T patent/DK0784483T3/da active
- 1995-10-02 CA CA002201587A patent/CA2201587C/en not_active Expired - Lifetime
- 1995-10-02 WO PCT/US1995/012624 patent/WO1996010419A2/en active IP Right Grant
- 1995-10-02 AU AU37353/95A patent/AU688606B2/en not_active Expired
- 1995-10-02 EP EP00102998A patent/EP1016418B1/en not_active Expired - Lifetime
- 1995-10-02 JP JP51210096A patent/JP3907698B2/ja not_active Expired - Lifetime
- 1995-10-02 AT AT95935264T patent/ATE197765T1/de active
- 1995-10-02 PT PT95935264T patent/PT784483E/pt unknown
-
2000
- 2000-01-07 US US09/480,340 patent/US6548068B1/en not_active Expired - Lifetime
-
2001
- 2001-02-22 GR GR20010400292T patent/GR3035458T3/el unknown
-
2003
- 2003-01-14 US US10/341,431 patent/US6893869B2/en not_active Expired - Lifetime
-
2004
- 2004-01-23 JP JP2004048693A patent/JP4078319B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-28 US US11/090,686 patent/US7368116B2/en not_active Expired - Lifetime
-
2006
- 2006-10-26 JP JP2006291632A patent/JP4160612B2/ja not_active Expired - Lifetime
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009254390A (ja) * | 1998-12-09 | 2009-11-05 | Usa Government | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
JP2008518583A (ja) * | 2003-05-16 | 2008-06-05 | アヴェンティス パストゥール インコーポレイテッド | 癌の予防または治療のための腫瘍抗原 |
JP2011067207A (ja) * | 2003-05-16 | 2011-04-07 | Sanofi Pasteur Inc | 癌の予防または治療のための腫瘍抗原 |
JP2012110328A (ja) * | 2003-05-16 | 2012-06-14 | Sanofi Pasteur Inc | 癌の予防または治療のための腫瘍抗原 |
JP2012524075A (ja) * | 2009-04-17 | 2012-10-11 | グローブイミューン,インコーポレイテッド | 癌に対する併用免疫療法組成物および方法 |
US10383924B2 (en) | 2009-04-17 | 2019-08-20 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
US10874729B2 (en) | 2009-04-17 | 2020-12-29 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
US11590216B2 (en) | 2009-04-17 | 2023-02-28 | GlobelImmune, Inc. | Combination immunotherapy compositions against cancer and methods |
US11596675B2 (en) | 2009-04-17 | 2023-03-07 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
JP2013528197A (ja) * | 2010-06-10 | 2013-07-08 | インターベツト・インターナシヨナル・ベー・ベー | 抗腫瘍組成物 |
JP2018515141A (ja) * | 2015-05-15 | 2018-06-14 | リーバー ジェネティクス シーオー., エルティーディー.Reber Genetics Co., Ltd. | 新規のバキュロウイルスベクター及び使用の方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0784483A2 (en) | 1997-07-23 |
US6893869B2 (en) | 2005-05-17 |
JP3907698B2 (ja) | 2007-04-18 |
JP2004222726A (ja) | 2004-08-12 |
WO1996010419A3 (en) | 1996-05-17 |
CA2201587C (en) | 2002-06-25 |
PT784483E (pt) | 2001-05-31 |
US20050186180A1 (en) | 2005-08-25 |
US7368116B2 (en) | 2008-05-06 |
US20050063993A1 (en) | 2005-03-24 |
DE69519521T2 (de) | 2001-06-28 |
GR3035458T3 (en) | 2001-05-31 |
DE69519521D1 (de) | 2001-01-04 |
US6548068B1 (en) | 2003-04-15 |
ATE197765T1 (de) | 2000-12-15 |
JP2007105045A (ja) | 2007-04-26 |
JP4078319B2 (ja) | 2008-04-23 |
AU688606B2 (en) | 1998-03-12 |
EP0784483B1 (en) | 2000-11-29 |
DK0784483T3 (da) | 2001-03-26 |
WO1996010419A2 (en) | 1996-04-11 |
AU3735395A (en) | 1996-04-26 |
CA2201587A1 (en) | 1996-04-11 |
EP1016418B1 (en) | 2009-12-30 |
EP1016418A2 (en) | 2000-07-05 |
EP1016418A3 (en) | 2004-03-03 |
JP4160612B2 (ja) | 2008-10-01 |
ES2154738T3 (es) | 2001-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3907698B2 (ja) | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 | |
US7662395B2 (en) | Method of enhancing a targeted immune response against tumors | |
US6001349A (en) | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof | |
AU712714B2 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system | |
US20030021770A1 (en) | Recombinant pox virus for immunization against MUC1 tumor-associated antigen | |
Akagi et al. | Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7 | |
JPH06508025A (ja) | 癌胎児性抗原を発現する組換えウイルスとその使用方法 | |
US20070048860A1 (en) | Carcinoembryonic antigen (CEA) peptides | |
CN109575143B (zh) | 双特异性cd20-cd19-car及其应用 | |
JP2002531133A (ja) | 複数の共刺激分子を発現する組換えベクターおよびその利用 | |
EP1021535A2 (en) | Human cancer antigen ny eso-1/cag-3 and gene encoding same | |
Kaufman et al. | Strategies for cancer therapy using carcinoembryonic antigen vaccines | |
Hurpin et al. | The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity | |
CA2252406A1 (en) | Heterologous boosting immunizations | |
WO1998015285A1 (en) | Methods and compositions for inducing a protective immune response to cancers | |
WO1998015285A9 (en) | Methods and compositions for inducing a protective immune response to cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040123 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040513 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060404 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060419 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061124 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070117 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110126 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120126 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130126 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |